Erratum to: The molecular landscape of head and neck cancer (Nature Reviews Cancer, (2018), 18, 5, (269-282), 10.1038/nrc.2018.11);The molecular landscape of head and neck cancer

Nature Reviews Cancer

Volumn 18, Issue 5, 2018, Pages 269-282

  Leemans, C René ^a   Snijders, Peter J F ^a   Brakenhoff, Ruud H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; WNT PROTEIN; CDKN2A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER;

EPIGENETICS; GENE DOSAGE; GENETIC HETEROGENEITY; GENOME ANALYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; VIRUS CARCINOGENESIS; WART VIRUS; WNT SIGNALING; CELL CYCLE; COMPLICATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEAD AND NECK TUMOR; IMMUNOTHERAPY; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROCEDURES; TUMOR SUPPRESSOR GENE; VIROLOGY;

BIOMARKERS, TUMOR; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; SQUAMOUS CELL CARCINOMA OF HEAD AND NECK; WNT SIGNALING PATHWAY;

EID: 85044319718     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/s41568-018-0057-9     Document Type: Erratum

References (139)

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386 (2015).
2. Castellsague, X. et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J. Natl. Cancer Inst. 108, djv403 (2016).
3. Lawrence, M. S. et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576-582 (2015). A report with what is currently the largest genomics data set of head and neck cancer.
4. Seiwert, T. Y. et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res. 21, 632-641 (2015).
5. Braakhuis, B. J. M. et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J. Natl Cancer Inst. 96, 998-1006 (2004). This study presents for the first time the major molecular difference between HPV+ve and HPV.ve HNSCC.
6. Smeets, S. J. et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25, 2558-2564 (2006).
7. Slebos, R. J. C. et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin. Cancer Res. 12, 701-709 (2006).
8. Wichmann, G. et al. The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int. J. Cancer 137, 2846-2857 (2015).
9. Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24-35 (2010).
10. Rietbergen, M. M. et al. Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment de-escalation trials. Ann. Oncol. 24, 2740-2745 (2013).
11. O'Sullivan, B. et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 17, 440-451 (2016).
12. Brierley, J. D. G., Gospodarowicz, M. K. & Wittekind, C. TNM Classification of Malignant Tumours 8th edn (Wiley-Blackwell, 2016).
13. Belbin, T. J. et al. Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res. 62, 1184-1190 (2002).
14. Chung, C. H. et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5, 489-500 (2004).
15. Walter, V. et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLOS ONE 8, e56823 (2013).
16. Keck, M. K. et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin. Cancer Res. 21, 870-881 (2015).
17. Schnitt, S. J. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern Pathol. 23, S60-S64 (2010).
18. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
19. Leemans, C. R., Braakhuis, B. J. M. & Brakenhoff, R. H. The molecular biology of head and neck cancer. Nat. Rev. Cancer 11, 9-22 (2011).
20. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
21. Brouns, E. R. E. A. et al. Malignant transformation of oral leukoplakia in a well-defined cohort of 144 patients. Oral Dis. 20, e19-e24 (2014).
22. Petti, S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol. 39, 770-780 (2003).
23. Napier, S. S. & Speight, P. M. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J. Oral Pathol Med. 37, 1-10 (2008).
24. van der Waal, I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 45, 317-323 (2009).
25. Slaughter, D. P., Southwick, H. W. & Smejkal, W. Field cancerization in oral stratified squamous epithelium - clinical Implications of multicentric origin. Cancer 6, 963-968 (1953).
26. Califano, J. et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 56, 2488-2492 (1996).
27. Tabor, M. P. et al. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin. Cancer Res. 10, 3607-3613 (2004).
28. Tabor, M. P. et al. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am. J. Pathol. 161, 1051-1060 (2002).
29. Tabor, M. P. et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin. Cancer Res. 7, 1523-1532 (2001).
30. Zhang, L. W. et al. Loss of Heterozygosity (LOH) profiles-validated risk predictors for progression to oral cancer. Cancer Prev. Res. 5, 1081-1089 (2012).
31. Graveland, A. P. et al. Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. Int. J. Cancer 128, 1852-1859 (2011).
32. Campbell, J. D. et al. The case for a pre-cancer genome atlas (PCGA). Cancer Prev. Res 9, 119-124 (2016).
33. Tomasetti, C., Li, L. & Vogelstein, B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 355, 1330-1334 (2017).
34. Tomasetti, C. & Vogelstein, B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78-81 (2015).
35. van Houten, V. M. M. et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J. Pathol. 198, 476-486 (2002).
36. Lim, X. H. et al. Interfollicular epidermal stem cells self-renew via autocrine Wnt signaling. Science 342, 1226-1230 (2013).
37. Beck, T. N. & Golemis, E. A. Genomic insights into head and neck cancer. Cancers Head Neck 1, 1 (2016).
38. Hayes, D. N., Van Waes, C. & Seiwert, T. Y. Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors. J. Clin. Oncol. 33, 3227-3236 (2015).
39. Toledo, L., Neelsen, K. J. & Lukas, J. Replication catastrophe: when a checkpoint fails because of exhaustion. Mol. Cell 66, 735-749 (2017).
40. Levine, A. J. & Oren, M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749-758 (2009).
41. Normanno, N. et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2-16 (2006).
42. Lin, S. Y. et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 3, 802-808 (2001).
43. Moser, R. et al. Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin. Cancer Res. 20, 4274-4288 (2014).
44. van Roy, F. & Berx, G. The cell-cell adhesion molecule E-cadherin. Cell. Mol. Life Sci. 65, 3756-3788 (2008).
45. Tanoue, T. & Takeichi, M. Mammalian Fat1 cadherin regulates actin dynamics & cell-cell contact. J. Cell Biol. 165, 517-528 (2004).
46. Morris, L. G. T. et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant WNT activation. Nat. Genet. 45, 253-261 (2013).
47. Clevers, H., Loh, K. M. & Nusse, R. An integral program for tissue renewal and regeneration: WNT signaling and stem cell control. Science 346, 54 (2014).
48. Schimizzi, G. V. & Longmore, G. D. Ajuba proteins. Curr. Biol. 25, R445-R446 (2015).
49. Hirota, T. et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114, 585-598 (2003).
50. Sun, G. P. & Irvine, K. D. Ajuba family proteins link JNK to Hippo signaling. Sci. Signal. 6, ra81 (2013).
51. Marie, H. et al. The LIM protein Ajuba is recruited to cadherin-dependent cell junctions through an association with alpha-catenin. J. Biol. Chem. 278, 1220-1228 (2003).
52. Kanungo, J., Pratt, S. J., Marie, H. & Longmore, G. D. Ajuba, a cytosolic LIM protein, shuttles into the nucleus and affects embryonal cell proliferation and fate decisions. Mol. Biol. Cell 11, 3299-3313 (2000).
53. Haraguchi, K. et al. Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3 betamediated phosphorylation of beta-catenin. Oncogene 27, 274-284 (2008).
54. Kopan, R. & Ilagan, M. X. G. The canonical NOTCH signaling pathway: unfolding the activation mechanism. Cell 137, 216-233 (2009).
55. Ntziachristos, P., Lim, J. S., Sage, J. & Aifantis, I. From fly wings to targeted cancer therapies: a centennial for NOTCH signaling. Cancer Cell 25, 318-334 (2014).
56. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
57. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011).
58. Sun, W. Y. et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 74, 1091-1104 (2014).
59. Nicolas, M. et al. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 33, 416-421 (2003).
60. Kwon, C. et al. Notch post-translationally regulates beta-catenin protein in stem and progenitor cells. Nat. Cell Biol. 13, 1244-1251 (2011).
61. Borggrefe, T. et al. The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGF beta/ BMP and hypoxia pathways. BBA Mol. Cell Res. 1863, 303-313 (2016).
62. Perri, F. et al. Epigenetic control of gene expression: potential implications for cancer treatment. Crit. Rev. Oncol. Hemat. 111, 166-172 (2017).
63. Ng, S. B. et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat. Genet. 42, 790-793 (2010).
64. Kurotaki, N. et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat. Genet. 30, 365-366 (2002).
65. Choufani, S. et al. NSD1 mutations generate a genome-wide DNA methylation signature. Nat. Commun. 6, 10207 (2015).
66. Lin, S. B. & Gregory, R. I. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 15, 321-333 (2015).
67. de Boer, D. V. et al. Targeting PLK1 as a novel chemopreventive approach to eradicate prenoplastic mucosal changes in the head and neck. Oncotarget 8, 97928-97940 (2017).
68. Smeets, S. J., Braakhuis, B. J. M., Ylstra, B., Leemans, C. R. & Brakenhoff, R. H. TP53 mutations are associated with a particular pattern of genomic imbalances in head and neck squamous cell carcinoma. Cell. Oncol. 29, 160-160 (2007).
69. Gross, A. M. et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat. Genet. 46, 939-943 (2014).
70. De Cecco, L. et al. Head and neck cancer subtypes with biological and clinical relevance: meta-analysis of geneexpression data. Oncotarget 6, 9627-9642 (2015).
71. Wilkerson, M. D. et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically Important, and correspond to normal cell types. Clin. Cancer Res. 16, 4864-4875 (2010).
72. Romero, R. et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat. Med. 23, 1362-1368 (2017).
73. Bar-Peled, L. et al. Chemical proteomics identifies druggable vulnerabilities in a genetically defined cancer. Cell 171, 696-709 (2017).
74. Gillison, M. L. et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92, 709-720 (2000).
75. Begum, S., Cao, D. F., Gillison, M., Zahurak, M. & Westra, W. H. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin. Cancer Res. 11, 5694-5699 (2005).
76. Kim, S. H. et al. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int. J. Cancer 120, 1418-1425 (2007).
77. D'Souza, G. et al. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356, 1944-1956 (2007).
78. Kreimer, A. R., Clifford, G. M., Boyle, P. & Franceschi, S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidem. Biomar. 14, 467-475 (2005).
79. Ndiaye, C. et al. HPV DNA, E6/E7 mRNA, and p16(INK4a) detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 15, 1319-1331 (2014).
80. Steenbergen, R. D. M., Snijders, P. J. F., Heideman, D. A. M. & Meijer, C. J. L. M. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat. Rev. Cancer 14, 395-405 (2014).
81. Rampias, T., Sasaki, C., Weinberger, P. & Psyrri, A. E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J. Natl Cancer Inst. 101, 412-423 (2009).
82. Chen, R. W. et al. Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue. J. Clin. Microbiol. 43, 1408-1410 (2005).
83. Palmer, E. et al. Human papillomavirus infection is rare in nonmalignant tonsil tissue in the UK: Implications for tonsil cancer precursor lesions. Int. J. Cancer 135, 2437-2443 (2014).
84. Combes, J. D. et al. Prevalence of human papillomavirus in tonsil brushings and gargles in cancer-free patients: The SPLIT study. Oral Oncol. 66, 52-57 (2017).
85. Kreimer, A. R. et al. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex. Transm. Dis. 37, 386-391 (2010).
86. Gillison, M. L. et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 307, 693-703 (2012).
87. Herfs, M. et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc. Natl Acad. Sci. USA 109, 10516-10521 (2012).
88. Woods, R. S. R. et al. Cytokeratin 7 in oropharyngeal squamous cell carcinoma: a junctional biomarker for human papillomavirus-related tumors. Cancer Epidem. Biomar. 26, 702-710 (2017).
89. Kang, S. Y. et al. Characterization of epithelial progenitors in normal human palatine tonsils and their HPV16 E6/E7-induced perturbation. Stem Cell Rep. 5, 1210-1225 (2015).
90. Mirabello, L. et al. HPV16 sublineage associations with histology-specific cancer risk using HPV wholegenome sequences in 3200 women. J. Natl. Cancer Inst. 108, djw100 (2016).
91. Mirabello, L. et al. HPV16 E7 Genetic conservation is critical to carcinogenesis. Cell 170, 1164-1174 (2017).
92. Chung, C. H. et al. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann. Oncol. 26, 1216-1223 (2015).
93. Smeets, S. J. et al. Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int. J. Cancer 128, 1596-1605 (2011).
94. Bader, A. G., Kang, S. Y., Zhao, L. & Vogt, P. K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5, 921-929 (2005).
95. Sewell, A. et al. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin. Cancer Res. 20, 2300-2311 (2014).
96. Henken, F. E. et al. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Mol. Cancer 10, 71 (2011).
97. Du, L. et al. Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF beta signaling. Oncogene 35, 4641-4652 (2016).
98. Woenckhaus, J. et al. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J. Pathol. 198, 335-342 (2002).
99. Verlaat, W. et al. Somatic mutation in PIK3CA is a late event in cervical carcinogenesis. J. Pathol. Clin. Res. 1, 207-211 (2015).
100. Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970-976 (2013).
101. Zhang, Y. X. et al. Subtypes of HPV-positive head and neck cancers are associated with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway signatures. Clin. Cancer Res. 22, 4735-4745 (2016).
102. Andor, N. et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat. Med. 22, 105-113 (2016).
103. Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104, 973-978 (2007).
104. Martensde Kemp, S. R. et al. CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell properties. Stem Cell Res. 10, 477-488 (2013).
105. Rietbergen, M. M. et al. Cancer stem cell enrichment marker CD98: a prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. Eur. J. Cancer 50, 765-773 (2014).
106. de Jong, M. C. et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin. Cancer Res. 16, 5329-5338 (2010).
107. Mroz, E. A. & Rocco, J. W. MATH, a novel measure of intratumor genetic heterogeneity, is high in pooroutcome classes of head and neck squamous cell carcinoma. Oral Oncol. 49, 211-215 (2013).
108. Mroz, E. A. et al. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 119, 3034-3042 (2013).
109. Mroz, E. A., Tward, A. M., Hammon, R. J., Ren, Y. & Rocco, J. W. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from The Cancer Genome Atlas. PLOS Med. 10, 1371 (2015).
110. Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611-1624 (2017).
111. Biddle, A. et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res. 71, 5317-5326 (2011).
112. Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl Med. 6, 224ra24 (2014).
113. Wang, Y. X. et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci. Transl Med. 7, 293ra104 (2015).
114. Principe, S. et al. Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discovery. Proteomics 13, 1608-1623 (2013).
115. Braakhuis, B. J. M. et al. Expression signature in peripheral blood cells for molecular diagnosis of head and neck squamous cell carcinoma. Oral Dis. 19, 452-455 (2013).
116. Best, M. G. et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28, 666-676 (2015).
117. Best, M. G. et al. Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumoreducated platelets. Cancer Cell 32, 238-252 (2017).
118. Ferris, R. L. Immunology and immunotherapy of head and neck cancer. J. Clin. Oncol. 33, 3293-3305 (2015).
119. Ferris, R. L. et al. Nivolumab for recurrent squamouscell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856-1867 (2016).
120. Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase-1b trial. Lancet Oncol. 17, 956-965 (2016).
121. Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275-287 (2016).
122. Budach, W. et al. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials. Radiother. Oncol. 118, 238-243 (2016).
123. Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
124. Schilling, C. et al. Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Eur. J. Cancer 51, 2777-2784 (2015).
125. Gan, S. J. et al. Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. Cancer 119, 2593-2601 (2013).
126. Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
127. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
128. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
129. Boscolo-Rizzo, P., Pawlita, M. & Holzinger, D. From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treat. Rev. 42, 24-29 (2016).
130. Rischin, D. Oropharyngeal cancer, human papillomavirus, and clinical trials. J. Clin Oncol. 28, 1-3 (2010).
131. van Houten, V. M. M. et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int. J. Cancer 93, 232-235 (2001).
132. Smeets, S. J. et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int. J. Cancer 121, 2465-2472 (2007). This study demonstrates simple solutions for the false-positive findings with HPV DNA testing and for the use of test algorithms with surrogate markers to assess HPV involvement in head and neck cancer.
133. Holzinger, D. et al. Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res. 72, 4993-5003 (2012).
134. McLaughlin-Drubin, M. E., Crum, C. P. & Mungera, K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl Acad. Sci. USA 108, 2130-2135 (2011).
135. Rietbergen, M. M. et al. Molecular characterization of p16-immunopositive but HPV DNA- negative oropharyngeal carcinomas. Int. J. Cancer 134, 2366-2372 (2014).
136. Prigge, E. S., Arbyn, M., Doeberitz, M. V. & Reuschenbach, M. Diagnostic accuracy of p16(INK4a) immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and metaanalysis. Int. J. Cancer 140, 1186-1198 (2017).
137. Rietbergen, M. M. et al. Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int. J. Cancer 132, 1565-1571 (2013).
138. Holzinger, D. et al. Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int. J. Cancer 140, 2748-2757 (2017).
139. Kreimer, A. R. et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J. Clin. Oncol. 31, 2708-2714 (2013).